check_circleStudy Completed

Hormone replacement therapy (HRT)

PK eval. of Angeliq - rel. BA/multiple PK

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
18
Trial Dates
September 2005 - December 2005
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

Open-label, randomized, cross-over study to evaluate the relative bioavailability (single dose, 1 tablet, in comparison to microcrystalline suspension) and to describe the pharmacokinetics (multiple dose, 28 days) of 17beta -estradiol (E2) and drospirenone (DRSP) after oral administration of a tablet formulation containing 1 mg E2 + 0.5 mg DRSP (SH T641A) in 18 healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A